Literature DB >> 27738951

Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.

Meng-Qing Gong1, Cong Wu1, Xiao-Yan He1, Jing-Yi Zong1, Jin-Long Wu1, Ren-Xi Zhuo1, Si-Xue Cheng2.   

Abstract

PURPOSE: To overcome multi-drug resistance (MDR) in tumor chemotherapy, a polymer/inorganic hybrid drug delivery platform with tumor targeting property and enhanced cell uptake efficiency was developed.
METHOD: To evaluate the applicability of our delivery platform for the delivery of different drug resistance inhibitors, two kinds of dual-drug pairs (doxorubicin/buthionine sulfoximine and doxorubicin/tariquidar, respectively) were loaded in heparin-biotin/heparin/protamine sulfate/calcium carbonate nanovesicles to realize simultaneous delivery of an anticancer drug and a drug resistance inhibitor into drug-resistant tumor cells.
RESULTS: Prepared by self-assembly, the drug loaded hybrid nanovesicles with a mean size less than 210 nm and a negative zeta potential exhibit good stability in serum contained aqueous media. The in vitro cytotoxicity evaluation indicates that hybrid nanovesicles with tumor targeting biotin moieties have an enhanced tumor cell inhibitory effect. In addition, dual-drug loaded hybrid nanovesicles exhibit significantly stronger cell growth inhibition as compared with doxorubicin (DOX) mono-drug loaded nanovesicles due to the reduced intracellular glutathione (GSH) content by buthionine sulfoximine (BSO) or the P-glycoprotein (P-gp) inhibition by tariquidar (TQR).
CONCLUSIONS: The tumor targeting nanovesicles prepared in this study, which can simultaneously deliver multiple drugs and effectively reverse drug resistance, have promising applications in drug delivery for tumor treatments. The polymer/inorganic hybrid drug delivery platform developed in this study has good applicability for the co-delivery of different anti-tumor drug/drug resistance inhibitor pairs to overcome MDR. Graphical Abstract A polymer/inorganic hybrid drug delivery platform with enhanced cell uptake was developed for tumor targeting synergistic drug delivery. The heparin-biotin/heparin/protamine sulfate/calcium carbonate nanovesicles prepared in this study can deliver an anticancer drug and a drug resistance inhibitor into drug-resistant tumor cells simultaneously to overcome drug resistance efficiently.

Entities:  

Keywords:  drug delivery; hybrid nanovesicles; multi-drug resistance; natural polymers

Mesh:

Substances:

Year:  2016        PMID: 27738951     DOI: 10.1007/s11095-016-2051-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

Review 1.  Nanoparticle delivery of cancer drugs.

Authors:  Andrew Z Wang; Robert Langer; Omid C Farokhzad
Journal:  Annu Rev Med       Date:  2011-09-01       Impact factor: 13.739

Review 2.  Smart chemistry in polymeric nanomedicine.

Authors:  Rong Tong; Li Tang; Liang Ma; Chunlai Tu; Ryan Baumgartner; Jianjun Cheng
Journal:  Chem Soc Rev       Date:  2014-06-19       Impact factor: 54.564

3.  Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.

Authors:  Niravkumar R Patel; Alok Rathi; Dmitriy Mongayt; Vladimir P Torchilin
Journal:  Int J Pharm       Date:  2011-06-15       Impact factor: 5.875

4.  Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.

Authors:  Fan Bai; Chao Wang; Qin Lu; Mei Zhao; Fu-Qiang Ban; De-Hong Yu; Ying-Yun Guan; Xin Luan; Ya-Rong Liu; Hong-Zhuan Chen; Chao Fang
Journal:  Biomaterials       Date:  2013-05-24       Impact factor: 12.479

Review 5.  Strategies for reversing drug resistance.

Authors:  Tito Fojo; Susan Bates
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

6.  Glutathione depletion by buthionine sulfoximine induces oxidative damage to DNA in organs of rabbits in vivo.

Authors:  Goksel Gokce; Gonen Ozsarlak-Sozer; Gulgun Oktay; Güldal Kirkali; Pawel Jaruga; Miral Dizdaroglu; Zeliha Kerry
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

Review 7.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.

Authors:  Charlene M Dawidczyk; Chloe Kim; Jea Ho Park; Luisa M Russell; Kwan Hyi Lee; Martin G Pomper; Peter C Searson
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

Review 8.  Inorganic nanoparticle-based drug codelivery nanosystems to overcome the multidrug resistance of cancer cells.

Authors:  Yu Chen; Hangrong Chen; Jianlin Shi
Journal:  Mol Pharm       Date:  2013-11-18       Impact factor: 4.939

9.  Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.

Authors:  Yogesh Patil; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  J Control Release       Date:  2009-02-05       Impact factor: 9.776

10.  Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging.

Authors:  Mya S Thu; L Henry Bryant; Tiziana Coppola; E Kay Jordan; Matthew D Budde; Bobbi K Lewis; Aneeka Chaudhry; Jiaqiang Ren; Nadimpalli Ravi S Varma; Ali S Arbab; Joseph A Frank
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

View more
  2 in total

Review 1.  Recent Progress on Heparin-Protamine Particles for Biomedical Application.

Authors:  Yuuki Hata; Hiromi Miyazaki; Masayuki Ishihara; Shingo Nakamura
Journal:  Polymers (Basel)       Date:  2022-02-25       Impact factor: 4.329

2.  Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based "combo" nanoagent together with PD-L1 blockade in reversing multidrug resistance.

Authors:  Weixi Jiang; Lei Su; Meng Ao; Xun Guo; Chen Cheng; Yuanli Luo; Zhuoyan Xie; Xingyue Wang; Junrui Wang; Shuling Liu; Yang Cao; Pan Li; Zhigang Wang; Haitao Ran; Zhiyi Zhou; Jianli Ren
Journal:  J Nanobiotechnology       Date:  2021-07-05       Impact factor: 10.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.